Abstract
Neurodegeneration is a multifactorial process involved the different cytotoxic pathways that lead to neuronal cell death. Alzheimer’s disease (AD) is a persistent neurodegenerative disorder that normally has a steady onset and gradually worsens. Neuropathology, AD is characterized by the presence of neuroinflammation, mitochondrial dysfunction, increased oxidative stress, decreased antioxidant defense as well as increased acetylcholinesterase activity. Moreover, enhanced expression of amyloid precursor proteins leads to neural apoptosis, which has a vital role in the degeneration of neurons. The inability of commercial therapeutics to treat a single feature of AD pathology leads to the attraction towards organic drugs. Ellagic acid is a dimer of gallic acid; latest studies revealed that ellagic acid can initiate numerous cell signaling transmissions and decrease the progression of neurodegeneration. The neuroprotective effects of ellagic acid to protect the neurons against neurodegenerative events are due to its antioxidant effect, iron chelating, and mitochondrial protective effect. The main goal of this review is to critically analyze the molecular mechanism of action of ellagic acid against AD.
Keywords: Ellagic acid, Alzheimer's disease, antioxidant activity, acetylcholinesterase, mitochondrial dysfunction, neurodegeneration, cell signaling.
Current Pharmaceutical Design
Title:Neuroprotective Effects of Ellagic Acid in Alzheimer's Disease: Focus on Underlying Molecular Mechanisms of Therapeutic Potential
Volume: 27 Issue: 34
Author(s): Nimra Javaid, Muhammad A. Shah*, Azhar Rasul, Zunera Chauhdary, Uzma Saleem, Haroon Khan, Nazir Ahmed, Md. Sahab Uddin, Bijo Mathew, Tapan Behl and Renald Blundell
Affiliation:
- Department of Pharmacognosy, Faculty of Pharmaceutical Sciences, Government College University, Faisalabad,Pakistan
Keywords: Ellagic acid, Alzheimer's disease, antioxidant activity, acetylcholinesterase, mitochondrial dysfunction, neurodegeneration, cell signaling.
Abstract: Neurodegeneration is a multifactorial process involved the different cytotoxic pathways that lead to neuronal cell death. Alzheimer’s disease (AD) is a persistent neurodegenerative disorder that normally has a steady onset and gradually worsens. Neuropathology, AD is characterized by the presence of neuroinflammation, mitochondrial dysfunction, increased oxidative stress, decreased antioxidant defense as well as increased acetylcholinesterase activity. Moreover, enhanced expression of amyloid precursor proteins leads to neural apoptosis, which has a vital role in the degeneration of neurons. The inability of commercial therapeutics to treat a single feature of AD pathology leads to the attraction towards organic drugs. Ellagic acid is a dimer of gallic acid; latest studies revealed that ellagic acid can initiate numerous cell signaling transmissions and decrease the progression of neurodegeneration. The neuroprotective effects of ellagic acid to protect the neurons against neurodegenerative events are due to its antioxidant effect, iron chelating, and mitochondrial protective effect. The main goal of this review is to critically analyze the molecular mechanism of action of ellagic acid against AD.
Export Options
About this article
Cite this article as:
Javaid Nimra , Shah A. Muhammad *, Rasul Azhar , Chauhdary Zunera , Saleem Uzma , Khan Haroon, Ahmed Nazir , Uddin Sahab Md. , Mathew Bijo , Behl Tapan and Blundell Renald , Neuroprotective Effects of Ellagic Acid in Alzheimer's Disease: Focus on Underlying Molecular Mechanisms of Therapeutic Potential, Current Pharmaceutical Design 2021; 27 (34) . https://dx.doi.org/10.2174/1381612826666201112144006
DOI https://dx.doi.org/10.2174/1381612826666201112144006 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Oxidative Stress and Cancer: The Role of Nrf2
Current Cancer Drug Targets Acetate Suppresses Lipopolysaccharide-stimulated Nitric Oxide Production in Primary Rat Microglia but not in BV-2 Microglia Cells
Current Molecular Pharmacology Ethanolamine: A Potential Promoiety with Additional Effects on the Brain
CNS & Neurological Disorders - Drug Targets Vasopressin in Health and Disease with a Focus on Affective Disorders
Central Nervous System Agents in Medicinal Chemistry Clinical Significance of Cytokines and Chemokines in Neuropsychiatric Systemic Lupus Erythematosus
Current Rheumatology Reviews Mitochondrial Disturbances, Tryptophan Metabolites and Neurodegeneration: Medicinal Chemistry Aspects
Current Medicinal Chemistry Patent Selections
Recent Patents on Nanotechnology Interlocked Systems in Nanomedicine
Current Topics in Medicinal Chemistry Pharmacophore, QSAR, and Binding Mode Studies of Substrates of Human Cytochrome P450 2D6 (CYP2D6) Using Molecular Docking and Virtual Mutations and an Application to Chinese Herbal Medicine Screening
Current Pharmaceutical Biotechnology Transplantation-Based Gene Therapy for Inflammatory Diseases Focus on Glomerulonephritis
Current Gene Therapy Aβ Oligomers Induce Glutamate Release from Hippocampal Neurons
Current Alzheimer Research Variability in Response to Cardiovascular Drugs
Current Clinical Pharmacology Characterization of Endogenous Neural Progenitor Cells after Experimental Ischemic Stroke
Current Neurovascular Research SARS-CoV-2 Induced Neurological Manifestations Entangles Cytokine Storm that Implicates for Therapeutic Strategies
Current Medicinal Chemistry Fetal Asphyctic Preconditioning Protects Against Perinatal Asphyxia- Induced Apoptosis and Astrogliosis in Neonatal Brain
CNS & Neurological Disorders - Drug Targets Interleukin-18, From Neuroinflammation to Alzheimers Disease
Current Pharmaceutical Design Conference Report: 12<sup>th</sup> International Congress on Neuroprotective Agents (ICNA), Charlottesville, VA, USA September 28, 2014-Ocobert 01, 2014
CNS & Neurological Disorders - Drug Targets Anti-Vascular Endothelial Growth Factor Treatment in Retinal Vein Occlusions
Current Drug Therapy Depressed Glucose Consumption at Reperfusion following Brain Ischemia does not Correlate with Mitochondrial Dysfunction and Development of Infarction: An in vivo Positron Emission Tomography Study
Current Neurovascular Research Glioma Therapy: A Novel Insight in the Immunotherapeutic Regime with T11TS/SLFA-3
Central Nervous System Agents in Medicinal Chemistry